In a report published today, Roth Capital analyst Scott Henry maintained a Buy rating on Lannett Company (LCI) with a $45 price target, …
In a research report issued today, Roth Capital analyst Scott Henry maintained coverage with a Buy rating on shares of Lannett Company (LCI) and $45 price target. The report follows Tuesday’s news …
In a research note issued this morning, Roth Capital analyst Scott Henry maintained coverage with a Buy rating on shares of InSite Vision (INSV), with a price target of …
In a research note issued this morning, Roth Capital analyst Scott Henry maintained a Buy rating on RedHill Biopharma (RDHL) and raised his price target …
In a research note released this morning, Roth Capital analyst Scott Henry maintained a Buy rating on BioDelivery Sciences (BDSI) and raised his price target …
In a research note released Tuesday, Roth Capital analyst Scott Henry maintained a Buy rating on ANI Pharmaceuticals (ANIP) and raised his price target to $40.00 (from $38.
In a research note released Tuesday, Roth Capital analyst Scott Henry maintained a Buy rating on Salix Pharmaceuticals (SLXP), and a 12 month price target of $130/share, following today’s news that SLXP’s Xifaxan …
In a research note released today, Roth Capital analyst Scott Henry maintained a Buy rating with a $20 price target following Flamel Technologies’ (FLML) the FDA …
In a research note issued this morning, Roth Capital analyst Scott Henry maintained a Buy rating on China Cord Blood Corporation (CO) and raised his price target to $6.00 (from $5.
In a research note released this morning, Roth Capital analyst Scott Henry reiterated coverage with a “Buy” rating on Derma Sciences Inc. (DSCI) and …
